Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0417 PK in Renal or Hepatic Impairment
NCT05731804Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simnotrelvir in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 48 hours and 1 more. Status: unknown.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05731804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731804.